GLP-1 Coverage Guide is a private website. We are not Medicare, the Centers for Medicare & Medicaid Services (CMS), or any government agency, and we are not affiliated with or endorsed by them.
Text size:

What happens when the Bridge ends

Short answer: Unless CMS extends it, the Bridge stops covering fills after December 31, 2027 — and patients mid-therapy will need a plan. The realistic options afterward: the standard Part D path if a routing diagnosis applies to you by then, manufacturer self-pay programs at several times the price, or whatever policy replaces the program. The right time to plan is while you're still covered.

Program facts last verified against CMS: July 21, 2026

The scenarios, honestly ranked

Scenario one — sunset without replacement (the default): fills after the end date fall to self-pay; at current manufacturer-direct prices that's a jump from $50 to several hundred monthly. Abrupt discontinuation typically means appetite effects fade and weight regain — so the exit conversation with your prescriber (taper strategy, maintenance alternatives, expectations) matters medically, not just financially. Scenario two — a successor program or extension: possible, unannounced, and not worth betting your planning on. Scenario three — individual rerouting: some patients will have developed routing diagnoses by then (type 2 diabetes among them), which moves their coverage to standard Part D under its own rules.

One more planning note: the program's final Open Enrollment (October–December 2027) happens while the end date looms. If your post-Bridge future involves the Part D path, that's the window to pick a plan whose formulary treats your likely medication well.

Take the 2-minute eligibility check →

Common questions

Will I get cut off mid-prescription?

The program's terms run through December 31, 2027 — fills through that date process normally. What no one can promise is anything after it; assume nothing and plan with your prescriber during 2027.

Should I even start therapy this late?

That's a real conversation with your prescriber — but note the arithmetic still favors starting: every covered month is therapy at $50 that would otherwise cost hundreds, and the clinical benefits accrue during treatment either way.

Is stockpiling fills an option?

The program dispenses monthly, and stockpiling injectables raises storage and safety issues besides. The better preparation is the exit-strategy conversation, not a stockpile.

Related

Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF